1. 消化系统肿瘤发生发展机制：胰腺癌铁死亡调控及胃癌、肝癌相关分子机制。

2. 肿瘤免疫与靶向治疗：肿瘤免疫微环境、CAR-T细胞治疗及单克隆抗体研究。

3. 消化系统肿瘤流行病学与预后：胰腺癌发病趋势、小肠腺癌转移模式及生存分析。

参与发表SCI论文17篇，其中以第一作者或共同第一作者（署名第一）发表3篇，以第二作者或共同第一作者（署名第二）发表9篇。参与申请发明专利3项，其中2项已获授权。

学术论文

1.    Gu Y, et al. Repurposing dronedarone induces ferroptosis through GPX4 inactivation and degradation in pancreatic cancer. Journal of Experimental and Clinical Cancer Research. 2026 Mar 14.（共同第一作者，署名第一）

2.    Gu Y, et al. Spatiotemporal trends in pancreatic cancer incidence from 2013 to 2023 in Gansu Province, Northwest China: A regional study. World Journal of Gastroenterology.（第一作者）

3.    Gu Y, et al. Metastasis Pattern and Survival Analysis in Primary Small Bowel Adenocarcinoma: A SEER-Based Study. Frontiers in Surgery. 2021;8:759162.（第一作者）

4.    Teng M, Gu Y, et al. Transforming the Tumor Microenvironment: An Outstanding AIE-Active Photosensitizer to Boost the Effectiveness of Immunotherapy. Small. 2025;21(26):e2503355.（第二作者）

5.    Chen C, Gu YM, et al. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology. 2021;10(1):1901434.（共同第一作者，署名第二）

6.    Zhao B, Gu Y, et al. Elucidating the molecular markers and biological pathways associated with extrahepatic cholangiocarcinoma: a transcriptome sequencing study. Frontiers in Oncology. 2024;14:1417374.（第二作者）

7.    Wang J, Gu Y, et al. P2RX4 promotes hepatocellular carcinoma progression via calcium-mediated PI3K/AKT activation and immune remodeling. World Journal of Surgical Oncology. 2025;23(1):363.（第二作者）

8.    Wang D, Gu Y, et al. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy. Frontiers in Oncology. 2022;12:844260.（共同第一作者，署名第二）

9.    Wang D, Gu Y, et al. MCEMP1 is a potential therapeutic biomarker associated with immune infiltration in advanced gastric cancer microenvironment. Gene. 2022;840:146760.（共同第一作者，署名第二）

10.  Liu T, Gu Y, et al. Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention. Medical Oncology. 2025;42(4):93.（第二作者）

11.  Liu T, Gu Y, et al. Integrin α2 in the microenvironment and the tumor compartment of digestive (gastrointestinal) cancers: emerging regulators and therapeutic opportunities. Frontiers in Oncology. 2024;14:1439709.（共同第一作者，署名第二）

12.  Huo C, Gu Y, et al. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer. J Cancer Res Clin Oncol. 2023;149(17):15335-15348.（第二作者）

13.  Huo C, Zhang X, Gu Y, et al. Organoids: Construction and Application in Gastric Cancer. Biomolecules. 2023;13(5).

14.  Guo L, Wang Z, Du Y, et al. Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma. Cancer Cell Int. 2020;20:251.

15.  Chen C, Zhang F, Zhou N, Gu YM, et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019;8(5):e1581547.

16.  Teng M, Li Z, Gu Y, et al. Real-time monitoring of glucose metabolism and effects of metformin on HepG2 cells using (13)C in-cell NMR spectroscopy. Biochem Biophys Res Commun. 2024;694:149383.

17.  Huo CD, Yang J, Gu YM, et al. Overcome tumor relapse in CAR T cell therapy. Clin Transl Oncol. 2022;24(10):1833-1843.

发明专利

1.    ITGA2单克隆抗体及其应用。专利号：CN119241709B；已授权；第二发明人。

2.    TPI1中和单克隆抗体及其制备方法和应用。专利号：CN117586405B；已授权；第三发明人。

3.    一种决奈达隆在诱导肿瘤细胞铁死亡中的应用及其筛选方法。实质审查阶段；第二发明人。